Business
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
BAAR, Switzerland, February 18, 2026--Evinova announces strategic collaborations with Astellas, AstraZeneca and Bristol Myers Squibb advancing its AI-native platform
About this update from Astellas Pharma Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5f118fc86a1a47e7b4545a467fe63088"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MplV8TWNAfUKWQyoM5qMKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5f118fc86a1a47e7b4545a467fe63088","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/IR4rWvz7iGg0k94BuFhpuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5f118fc86a1a47e7b4545a467fe63088","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BAAR, Switzerland, February 18, 2026--(BUSINESS WIRE)--Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. ("Astellas"), AstraZeneca and Bristol Myers Squibb to accelerate their global clinical development using Evinova’s AI-native platform. Each partner company has opted in to share operational data with Evinova, enabling the platform to provide benchmarks and smarter recommendations intended to further accelerate clinical trials and improve patient outcomes.","length":528,"tagName":"p"},{"type":"text","content":"Reimagining Clinical Development Through Collaboration","length":54,"tagName":"p"},{"type":"text","content":"Clinical development is often slowed by fragmented systems and manual processes that delay timelines and increase costs. Evinova's AI-native platform addresses these challenges through intelligent optimization, faster end-to-end workflows and recommendations for improvements. The platform, now enhanced with multi-agent AI capabilities, empowers partners to innovate, adapt, and achieve better outcomes.","length":408,"tagName":"p"},{"type":"text","content":"Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "This strategic collaboration with Evinova harnesses AI to accelerate clinical development, which we believe will significantly improve productivity gains, deliver faster trials, and enhance patient experience. More broadly, the AI-era will empower us to demonstrate the continued excellence of our science and the benefits it can deliver, fundamentally improving patient care in clinical development and ...